Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report

Exec Edge

03-27

Visit Exec Edge Research for Full Report

By Exec Edge Research

Climb Bio, Inc. (Nasdaq: CLYM) reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025.

As we highlighted in our 66-page initiation report last week (download here), CLYM’s lead asset is Budoprutug, an anti-CD19 monoclonal antibody engineered to target diseases such as membranous nephropathy (MN), systemic lupus erythematosus and lupus nephritis (SLE/LN), and immune thrombocytopenia (ITP). The company now has regulatory clearance from the FDA for clinical trials in all three of those indications and continues to strengthen the budoprutug IP. It has begun initiating clinical trials and expects to dose patients later this year.

Importantly, CLYM has cash on its balance sheet totaling $212.5 million, up from $106.8 million as of the end of 2023. Per the management, these funds are expected to be sufficient to fund the company’s planned operations through 2027. Please click the link below to read the detailed quarterly update report.

Visit Exec Edge Research for Full Report

Executives-Edge.com

Rayk@capmarketsmedia.com

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2522359149"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522359149\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2522359149?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-27 04:38","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2522359149","market":"nz","top_or_hot":-1,"title":"Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report","media":"Exec Edge","content":"<html><body><p><img height=\"533\" src=\"https://s.yimg.com/uu/api/res/1.2/ek1tHlISqTDMs3lK7cRFmg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/exec_edge_220/a57d3f3d79919df2be9669d4d4605a19\" width=\"800\"/></p>\n<div>\n<div>\n<div>\n<form action=\"\" method=\"post\">\n<div>\n<span></span>\n<span></span>\n<span></span>\n</div>\n<div>\n<div>\n<div>\n<span><i></i></span>\n</div>\n<h2>Enter your email to download the full report</h2>\n<div>\n<div>\n<label for=\"stu_name\">Your Name</label>\n<input type=\"text\"/>\n</div>\n<div>\n<label for=\"stu_email\">Your Email</label>\n<input/>\n</div>\n</div>\n<div>\n<div>\n<label for=\"stu_custom_field_lPY9T\">Your Company</label>\n<input type=\"text\"/>\n</div>\n</div>\n<div>\n<input type=\"submit\" value=\"Submit\"/>\n</div>\n</div>\n</div>\n<span>\n<div>\n      Loading...\n     </div> </span>\n<div></div>\n</form>\n</div>\n</div>\n<div>\n<h1>Visit Exec Edge Research for Full Report</h1>\n</div>\n</div>\n<p>By Exec Edge Research</p>\n<p>Climb Bio, Inc. (Nasdaq: CLYM) reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025.</p>\n<p>As we highlighted in our 66-page initiation report last week (<strong>download here</strong>), CLYM’s lead asset is Budoprutug, an anti-CD19 monoclonal antibody engineered to target diseases such as membranous nephropathy (MN), systemic lupus erythematosus and lupus nephritis (SLE/LN), and immune thrombocytopenia (ITP). The company now has regulatory clearance from the FDA for clinical trials in all three of those indications and continues to strengthen the budoprutug IP. It has begun initiating clinical trials and expects to dose patients later this year.</p>\n<p>Importantly, CLYM has cash on its balance sheet totaling $212.5 million, up from $106.8 million as of the end of 2023. Per the management, these funds are expected to be sufficient to fund the company’s planned operations through 2027. Please click the link below to read the detailed quarterly update report.</p>\n<div>\n<div>\n<div>\n<form action=\"\" method=\"post\">\n<div>\n<span></span>\n<span></span>\n<span></span>\n</div>\n<div>\n<div>\n<div>\n<span><i></i></span>\n</div>\n<h2>Enter your email to download the full report</h2>\n<div>\n<div>\n<label for=\"stu_name\">Your Name</label>\n<input type=\"text\"/>\n</div>\n<div>\n<label for=\"stu_email\">Your Email</label>\n<input/>\n</div>\n</div>\n<div>\n<div>\n<label for=\"stu_custom_field_lPY9T\">Your Company</label>\n<input type=\"text\"/>\n</div>\n</div>\n<div>\n<input type=\"submit\" value=\"Submit\"/>\n</div>\n</div>\n</div>\n<span>\n<div>\n      Loading...\n     </div> </span>\n<div></div>\n</form>\n</div>\n</div>\n<div>\n<h1>Visit Exec Edge Research for Full Report</h1>\n</div>\n</div>\n<p>Executives-Edge.com</p>\n<p>Rayk@capmarketsmedia.com</p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClimb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-27 04:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/climb-bio-fueled-cash-poised-203855757.html><strong>Exec Edge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Enter your email to download the full report\n\n\nYour Name\n\n\n\nYour Email\n\n\n\n\n\nYour Company\n\n\n\n\n\n\n\n\n\n\n      Loading...\n      \n\n\n\n\n\nVisit Exec Edge Research for Full Report\n\n\nBy Exec Edge Research\nClimb ...</p>\n\n<a href=\"https://finance.yahoo.com/news/climb-bio-fueled-cash-poised-203855757.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/climb-bio-fueled-cash-poised-203855757.html","article_id":"2522359149","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522359149","pubTimestamp":1743021535,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Climb Bio, Inc.  reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025.As we highlighted in our 66-page initiation report last week , CLYM’s lead asset is Budoprutug, an anti-CD19 monoclonal antibody engineered to target diseases such as membranous nephropathy , systemic lupus erythematosus and lupus nephritis , and immune thrombocytopenia . The company now has regulatory clearance from the FDA for clinical trials in all three of those indications and continues to strengthen the budoprutug IP. It has begun initiating clinical trials and expects to dose patients later this year.Importantly, CLYM has cash on its balance sheet totaling $212.5 million, up from $106.8 million as of the end of 2023. Per the management, these funds are expected to be sufficient to fund the company’s planned operations through 2027. Please click the link below to read the detailed quarterly update report.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ITP":"IT科技包装","CLYM":"CLIMB BIO INC","BK4199":"纸制品"},"translate_title":"Climb Bio注入现金，准备在25季度更新报告中实现更多里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLYM":0.9,"ITP":1},"content_text":"Enter your email to download the full report\n\n\nYour Name\n\n\n\nYour Email\n\n\n\n\n\nYour Company\n\n\n\n\n\n\n\n\n\n\n      Loading...\n      \n\n\n\n\n\nVisit Exec Edge Research for Full Report\n\n\nBy Exec Edge Research\nClimb Bio, Inc. (Nasdaq: CLYM) reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025.\nAs we highlighted in our 66-page initiation report last week (download here), CLYM’s lead asset is Budoprutug, an anti-CD19 monoclonal antibody engineered to target diseases such as membranous nephropathy (MN), systemic lupus erythematosus and lupus nephritis (SLE/LN), and immune thrombocytopenia (ITP). The company now has regulatory clearance from the FDA for clinical trials in all three of those indications and continues to strengthen the budoprutug IP. It has begun initiating clinical trials and expects to dose patients later this year.\nImportantly, CLYM has cash on its balance sheet totaling $212.5 million, up from $106.8 million as of the end of 2023. Per the management, these funds are expected to be sufficient to fund the company’s planned operations through 2027. Please click the link below to read the detailed quarterly update report.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nEnter your email to download the full report\n\n\nYour Name\n\n\n\nYour Email\n\n\n\n\n\nYour Company\n\n\n\n\n\n\n\n\n\n\n      Loading...\n      \n\n\n\n\n\nVisit Exec Edge Research for Full Report\n\n\nExecutives-Edge.com\nRayk@capmarketsmedia.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}